Nursing Care

Seizure precautions

studies complete Aspiration precautions

puberty

first 24 hrs

•Bed rest (Fall precautions) Compression stockings and/or medical DVT prophylaxis if post

•NPO until emergent diagnostic

Total Care Sports Specialty bed

Medications

Seizures (see AEDs for ICU):

Phenobarbital 20mg/kg x1

Diagnostic Guidelines

•HCT without contrast to rule out

•MRI brain and spine with and

•MRS if suspicion for metabolic

•MRI Q 2-4 weeks during initial

Laboratory Studies

Supportive Care · Ophthalmology consult (no dila-

•Call lab to prioritize studies •Place order to freeze extra CSF

dose) PRN seizure

day divided BID

Neuroimaging:

infection/tumor

without contrast

ICU admission

Electrophysiology:

hrs or until awake

tion for 1st 48hrs)

hospitalization

PM&R

PT/OT/Speech consult

Child life for family support

PANDA consult for prolonged

PT/OT and early mobilization

 Minimize restraints Minimize benzodiazepines •Consider melatonin at bedtime

Delirium Management

bleed

process




Table 1- Diagnostic Tests for Infectious Causes of Encephalitis (use ACUTE ENCEPHALOPATHY order set)

Priority may change based on history, exposures and clinical exam. Please confirm priority with ID and Neurology consultants prior to ordering

Organism	Blood	CSF	Other
Tier 1 Infectious Panel			
Meningitis/Encephalitis PCR (biofire)		Enterovirus E. coli Haemophilus influenza Listeria Neisseria meningitides Strep agalactiae Strep pneumo Cytomegalovirus HSV 1 and 2 HHV 6 Parechovirus VZV Cryptococcus	Ophtho exam if suspected CMV
HSV		CSF	Please send separately even though Included in the biofire
CMV	serology	Included in biofire	
VZV	serology	Included in biofire	
EBV	PCR	PCR	EBV PCR (CSF) must be ordered misc
Enterovirus	PCR	Included in biofire	
Arbovirus (West Nile, La Crosse, EEE, WEE, SLE)**	WNV serology***, arboviral serology,	WNV serology*** Arboviral serology	Arboviral IgM (CSF) must be ordered misc
Respiratory viruses			Nasal Respiratory Viral PCR, CXR
Mycoplasma	serology	PCR	NP PCR, CXR
Tier 2 Infectious Panel			
Bartonella	serology		Ophtho exam if suspected
HIV	serology and DNA PCR	DNA PCR	HIV DNA PCR (CSF)
Lyme	EIA screen serology with reflex WB	EIA screen serology with reflex WB	Ophtho exam if suspected
Mycobacterium TB		PCR, AFB smear and culture	PPD, CXR, PCR and culture of respiratory secretions PCR (CSF) must be ordered misc
Rickettsia**- RMSF, Ehrlichia, Anaplasma	RMSF serology, Ehrlichia serology, anaplasma serology	CSF PCR's all low yield	Review blood smear for morula if suspected anaplasma

List continues on page 3...

^{**} Repeat serologic testing recommended 10-21 days after initial presentation

^{***} WNV is not included in the arboviral panel (although it

Tier 3 Infectious Panel	Blood	CSF	Other
Malaria	Thin and Thick Smears		
Rotavirus			Stool/rectal rotavirus antigen
Parvovirus	serology and PCR	PCR	Highest risk in neonates
Rabies			Conjunctiva and Saliva PCR
Syphilis	VDRL or RPR w/ FTA- ABS if +	CSF VDRL	
Endemic Fungi- Histoplasma, Coccidioides		Histo antigen and serology	Urine Histo antigen
Amoeba- Naegleria, Balamuthia	Balamuthia serology (IFA) via CDC	Naegleria wet prep	Balamuthia, Naegleria (Cx), Amoeba Wet Prep must be or- dered misc
Immunocompromised Host			
HHV-6		Included in biofire	
West Nile Virus		PCR	
Cryptococcus	Cryptococcal Antigen	Included in biofire	CXR
JC-Virus		JCV PCR	
Toxoplasma	Toxoplasma serology	Toxo PCR	Ophtho exam
Amoeba- Acanthamoeba		Wet prep	Must be ordered as misc test

Labs to obtain PRIOR to IVIG

Infectious studies with titers

- * Labs to be determined based on presentation
- ** Obtain ID recommendations prior to administering IVIG (e.g. HIV, Lyme, Arbovirus, EBV, coxsackie)

Inflammatory studies with titers


SERUM CSF

ANA
ds- DNA,
TPO/ anti-thyroglobulin
Encephalopathy, Autoimmune Evaluation (ENS1)
NMO Ab (AQP4)
Anti MOG Ab
Antiphospholipid Ab
Oligoclonal bands
IgG synthesis
Immunoglobulins (IGAM)

Encephalopathy, Autoimmune Evaluation (ENC1) Oligoclonal bands IgG synthesis

Diagnostic studies for inflammatory causes of encephalopathy /encephalitis

Serum	CSF
General screening labs for consideration of non-in	fectious encephalitis (primary and/or secondary)
Immunoglobulins, ESR, CRP, ANA, ds- DNA, C3/4, ACE, TPO/ anti-thyroglobulin lactate/pyruvate battery, carnitine (free and total)	Neopterin Lactate Cytology
Oligoclonal bands and IgG Index (to be done at the same time as CSF)	Oligoclonal bands and IgG Index (to be done at the same time as serum)
	Encephalopathy, Autoimmune Evaluation (ENC1) **If unable to tap, send Serum Encephalopathy, Autoimmune Evaluation (ENS1) (send before IVIG)
Specific diagnoses based on clinical presentation a	nd course
Demyelinating brain or spine lesions, visual impairment - NMO Ab (AQP4)	- NMO Ab (AQP4)
Demyelinating lesion brain or spine (including ADEM) - Anti MOG Ab	- Anti MOG
Brainstem lesions or GBS like symptoms - GQ1B	- GQ1B
Acute psych disease, movement d/o, dysautonomia - NMDA Ab	- NMDA Ab
FIRES or prominent seizures - genetic epilepsy panel	- Cytokines CSF 1mL (Cincinnati Childrens test #5863724)
Multiorgan failure in FIRES TG Ferritin HLH screening (Cincinnati) Soluble IL2 –R	
Prominent cerebral edema, necrotizing lesions, prominent thalamic lesions and/or flu positive RANBP2 gene (ANE)	
Rash, autoimmune disease, suspect vasculitis Personalized gene sequencing panel for vasculitis Antiphospholipid Ab Beta 2 glycoprotein ANCA panel ENA (RNP, Sm) ENA 1 (SSA/SSB)	



NMDA Management

TIMELINE: Presumed antibody mediated encephalopathy including NMDA

WEEK 1:

Day 1 and 2: EEG monitoring for at least 24 hours to confirm presence/absence of seizures

MRI brain with and without contrast

Start pulse steroids (see page 8 for dosing after screening for TB risk)

Start IVIG (see page 8 for dosing)

- ** SEND antibody LABS prior to IVIG **
- ** Confirm all antibody labs are received with the lab (call for any order not in process in CERNER)

Minimize sedation

Assess for and treat dysautonomia, sleep disturbance and/or delirium

If symptoms severe consider PLEX prior to IVIG (e.g. if dysautonomia)

WEEK 2: Repeat MRI brain (+/- spine) with and without contrast

If no significant improvement and/or moderate to severe impairment, start Rituximab (see page 8 for dosing)

WEEK 4: If no significant improvement and/or moderate to severe impairment, start Cytoxan

* Once NMDAR encephalitis confirmed, begin tumor surveillance

FIRES Management

FIRES criteria

SRSE (must have failed wean of 3rd line agent)

Age 3-17

Seizures preceded by febrile illness

No alternative diagnosis despite comprehensive evaluation for infectious and inflammatory causes of seizures

Strategies for weaning infusion medications

Phenobarbital with goal levels ~ 100

Felbamate with goal levels > 50 (fosphenytoin drives level down)

Avoid propofol (due to concerns for secondary mitochondrial injury and propofol infusion syndrome)

Start metabolic supplements (see page 8)

Start ketogenic diet

Start aggressive bowel regimen (if being fed enterally).

* ILEUS IS NOT COMPATIBLE WITH ENTERAL AED ADMINISTRATION

Attend to parental inquiries regarding cannabadiols.

Bolus ketamine 1 mg/kg and begin infusion 1 mg/kg/hr (titrate to max of 10 mg/kg/hr)

Avoid polypharmacy, limit background AEDs to 4

Strategies for reducing inflammation

Begin pulse dose steroids (see page 8 for dosing)

Begin IVIG 2g/kg div 2 days as soon as labs sent (must confirm they are received in the lab and being processed)

Begin Anakinra (5 mg/kg/dose BID) once FIRES suspected

Consider PLEX if hemodynamically stable (will need to get AED labs post PLEX and bolus immediately after infusion) - anticipate timing for line placement and transfusion team preparation.

Consider Cytoxan if seizures continue to be refractory beyond week 3

Monitoring

Switch EEG to double distance once burst suppressed

Scalp breaks should be given every 4 days (minimum 4 hours)

Daily am trough for AED levels (phenobarbital, phenytoin, VPA)

Felbamate and Topiramate levels Monday and Thursday

High index of suspicion for DRESS (monitor for rash), HLH (multiorgan failure, increased TG and ferritin), dysautonomia (including gut dysmotility)

MRI brain every 2-4 weeks during initial PICU admission

Immune Modulating Therapies

Medication	Dose	Side Effects	Miscellaneous
IVIG	1g/kg IV Q day x 2 days, then once monthly x 6 months	Hypersensitivity/infusion reactions, hypotension, headache, aseptic meningitis	Order all titer studies prior to administration.
MethylPREDnisolone	30 mg/kg/day daily x 5 days (max: 1 gm daily)	HTN, immunosuppression, hyperglycemia, gastritis	Consider risk factors for TB and HSV Avoid if lymphoma included in DDX Concurrent admin of GI prophylaxis
Plasma exchange (PLEX)	Typically 5 rounds, every other day	Hemodynamic instability, bleeding (large catheter), possible drug removal	Requires catheter placement If young child or agitated need sitter for line safety Consider repeat IVIG after PLEX finished
RiTUXimab	750mg/m2/dose Q 2 weeks x 2 (max: 1000mg/dose)	Immune suppression, hypersensitivity/infusion reactions, PML (rare)	Counsel family on rare risk for PML Lymphocyte subset panel #1 pre and 3 months post infusion
Anakinra	3-5mg/kg SQ BID (max: 200mg/day)	Injection site reactions	Send CSF and serum cytokines to Cincinnati
Cyclophosphamide (Cytoxan)	500mg/m2 monthly x 6 months (max: 2500mg)	Immune suppression, nausea, vomiting, hemor- rhagic cystitis	Abx prophylaxis Counsel family on theoretical risk for infertility (females)

Metabolic Supplements for FIRES or similar presentation

Medication	Indication	Dose
Levocarnitine	Secondary mitochondrial dysfunction	50 mg/kg/day divided Q6 hours
Thiamine	Secondary mitochondrial dysfunction	100 mg daily
CoenzymeQ	Secondary mitochondrial dysfunction	5 mg/kg/day divided Q12 hours
Pyridoxine	Pyridoxine responsive seizures suspected	100 mg daily

Encephalopathy ≥24 hrs AND ≥1 of the following:

•Focal neurological findings

•T ≥ 38C •Seizures

Clinical Documentation Recommendations

•CSF pleocytosis or elevated protein	
Focal EEG or epileptiform activity	
Abnormal neuroimaging	
Diagnostic criteria met: Y/N	
<u>History</u> :	
Prodrome: Fever or illness w	rithin 10 days of presentation Y/N
Developmentally normal price	or to presentation: Y/N
Clinical findings:	
Fever during the first 24 hou	rs of admission (≥ 38) Y/N
Rash Y/N Date noted	
Course:	
Seizure during hospitalization	n Y/N Date first Date last
ICU admission Y/N	
G tube Y/N	
Trach Y/N	
Pacemaker Y/N	
Diagnostic work up:	
CSF: Y/N Dates	
EEG Y/N Dates	
Genetic labs (any) Y/N	
MRI brain Y/N Date	
<u>Treatment</u> :	
	e started c Number of days of therapy
Immune modulating therapy	
IVIG Y/N date	
Steroids Y/N date	
PLEX Y/N date_	
Anakinra Y/N date	
Rituximab Y/N d	ate